Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc., (GBT) (NASDAQ: GBT) today announced that it will host an Analyst & Investor Day to provide an update to the investment community on the company’s development and commercial strategy fo...
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Cantor Global Healthcare Conference in New York City on Wednesday, October 2, 2019, at 10:05 a.m. Eastern Time. The present...
The following slide deck was published by Global Blood Therapeutics, Inc. in conjunction with this Read more ...
On September 5 th , Global Blood Therapeutics, Inc. ( GBT ) publicized that the FDA had accepted Voxelotor’s NDA and granted it priority review status, which cuts the review cycle from 10 months to 6 months. Voxelotor is an oral, once-daily therapy for sickle cell disease, or “...
Global Blood Therapeutics (NASDAQ: GBT ) is up another 3.4% after hours, adding on to today's 10.9% gain fueled by FDA acceptance of a marketing application to apply voxelotor to sickle cell disease. More news on: Global Blood Therapeutics, Inc., Healthcare stocks news, Stocks on the...
Signet Jewelers (NYSE: SIG ) +29% on Q2 results . More news on: Signet Jewelers Limited, Edesa Biotech, Inc., Global Blood Therapeutics, Inc., Stocks on the move, Read more ...
Priority Review Shortens FDA Review Time to Six Months from Standard 10 Months NDA Supported by Data from Phase 3 HOPE Study, which Demonstrated Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor SOUTH SAN FRANCISCO, Calif., Sept. 05, 2019 (GLOBE NE...
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 2019 Morgan Stanley Global Healthcare Conference in New York City on Monday, September 9, 2019, at 2:50 p.m. Eastern Time. The p...
Patient Advocates, Healthcare Providers and Policy Makers to Discuss the Latest Advances and Future Trends for Treating Patients with SCD Conference Taking Place During National Sickle Cell Awareness Month Livestream of Conference will be Available through Collaboration with Sickl...
Global Blood Therapeutics (NASDAQ: GBT ): Q2 GAAP EPS of -$1.01 misses by $0.06 . More news on: Global Blood Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...